Using physiologically‐based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet
Abstract A combination of olanzapine and samidorphan (OLZ/SAM) was recently approved by the US Food and Drug Administration for treatment of patients with schizophrenia or bipolar I disorder. The effects of moderate hepatic impairment on the pharmacokinetics (PKs) of olanzapine and samidorphan after...
שמור ב:
| Principais autores: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Wiley
2021-09-01
|
| סדרה: | CPT: Pharmacometrics & Systems Pharmacology |
| גישה מקוונת: | https://doi.org/10.1002/psp4.12675 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|